Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...

Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...

Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

The company’s lead asset, CNM-Au8, is showing potential efficacy in treating amyotrophic lateral sclerosis (ALS), with plans for a New Drug Application (NDA) filing in mid-2025. This move is backed by ...

The research, led by the ALS Association in collaboration with several leading ALS clinicians, examined Medicare claims made from 2011 to 2021 and found that the average time for ...

Scientists are uncovering new insights into the mechanisms driving neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These fatal diseases ...

Data from over 8,000 ALS patients will be fed into Unlearn's Digital Twin Generator, an AI platform that creates duplicates ...

Fans are curious to know why Gregory Chase portrayed by Gregory Harrison leaves General Hospital. Introduced in 2018, he was ...